Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 117

1.

The PERSONS score: A new tool for cancer patients' symptom assessment in simultaneous care and home care settings.

Cortellini A, Porzio G, Cofini V, Necozione S, Parisi A, Peris F, Ravoni G, Spinelli G, Masel EK, Berghoff AS, Ficorella C, Verna L.

Palliat Support Care. 2019 Aug 22:1-6. doi: 10.1017/S1478951519000543. [Epub ahead of print]

PMID:
31434598
2.

Immune checkpoint inhibitor treatment in patients with oncogene- addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion.

Berghoff AS, Bellosillo B, Caux C, de Langen A, Mazieres J, Normanno N, Preusser M, Provencio M, Rojo F, Wolf J, Zielinski CC.

ESMO Open. 2019 Jun 17;4(3):e000498. doi: 10.1136/esmoopen-2019-000498. eCollection 2019. Review.

3.

New emerging targets in cancer immunotherapy: the role of Cluster of Differentiation 40 (CD40/TNFR5).

Piechutta M, Berghoff AS.

ESMO Open. 2019 Jun 12;4(Suppl 3):e000510. doi: 10.1136/esmoopen-2019-000510. eCollection 2019. Review.

4.

Noninvasive Differentiation of Meningiomas and Dural Metastases Using Intratumoral Vascularity Obtained by Arterial Spin Labeling.

Furtner J, Oth I, Schöpf V, Nenning KH, Asenbaum U, Wöhrer A, Woitek R, Widhalm G, Kiesel B, Berghoff AS, Hainfellner JA, Preusser M, Prayer D.

Clin Neuroradiol. 2019 Jun 26. doi: 10.1007/s00062-019-00808-x. [Epub ahead of print]

PMID:
31263906
5.

Quantitative evidence for early metastatic seeding in colorectal cancer.

Hu Z, Ding J, Ma Z, Sun R, Seoane JA, Scott Shaffer J, Suarez CJ, Berghoff AS, Cremolini C, Falcone A, Loupakis F, Birner P, Preusser M, Lenz HJ, Curtis C.

Nat Genet. 2019 Jul;51(7):1113-1122. doi: 10.1038/s41588-019-0423-x. Epub 2019 Jun 17.

PMID:
31209394
6.

Does neoadjuvant anti-PD1 therapy improve glioblastoma outcome?

Berghoff AS, Preusser M.

Nat Rev Neurol. 2019 Jun;15(6):314-315. doi: 10.1038/s41582-019-0178-0. No abstract available.

PMID:
30936570
7.

Correlated MRI and Ultramicroscopy (MR-UM) of Brain Tumors Reveals Vast Heterogeneity of Tumor Infiltration and Neoangiogenesis in Preclinical Models and Human Disease.

Breckwoldt MO, Bode J, Sahm F, Krüwel T, Solecki G, Hahn A, Wirthschaft P, Berghoff AS, Haas M, Venkataramani V, von Deimling A, Wick W, Herold-Mende C, Heiland S, Platten M, Bendszus M, Kurz FT, Winkler F, Tews B.

Front Neurosci. 2019 Jan 10;12:1004. doi: 10.3389/fnins.2018.01004. eCollection 2018.

8.

Continued Endocrine Therapy Is Associated with Improved Survival in Patients with Breast Cancer Brain Metastases.

Bergen ES, Berghoff AS, Medjedovic M, Rudas M, Fitzal F, Bago-Horvath Z, Dieckmann K, Mader RM, Exner R, Gnant M, Zielinski CC, Steger GG, Preusser M, Bartsch R.

Clin Cancer Res. 2019 May 1;25(9):2737-2744. doi: 10.1158/1078-0432.CCR-18-1968. Epub 2019 Jan 15.

PMID:
30647078
9.

High correlation of temporal muscle thickness with lumbar skeletal muscle cross-sectional area in patients with brain metastases.

Leitner J, Pelster S, Schöpf V, Berghoff AS, Woitek R, Asenbaum U, Nenning KH, Widhalm G, Kiesel B, Gatterbauer B, Dieckmann K, Birner P, Prayer D, Preusser M, Furtner J.

PLoS One. 2018 Nov 29;13(11):e0207849. doi: 10.1371/journal.pone.0207849. eCollection 2018.

10.

Brain metastases as first manifestation of advanced cancer: exploratory analysis of 459 patients at a tertiary care center.

Füreder LM, Widhalm G, Gatterbauer B, Dieckmann K, Hainfellner JA, Bartsch R, Zielinski CC, Preusser M, Berghoff AS.

Clin Exp Metastasis. 2018 Dec;35(8):727-738. doi: 10.1007/s10585-018-9947-1. Epub 2018 Nov 12.

11.

Chordoid meningiomas can be sub-stratified into prognostically distinct DNA methylation classes and are enriched for heterozygous deletions of chromosomal arm 2p.

Sievers P, Stichel D, Hielscher T, Schrimpf D, Reinhardt A, Wefers AK, Reuss D, Jones DTW, Bewerunge-Hudler M, Hartmann C, Baumgarten P, Wirsching HG, Winther-Kristensen B, Brokinkel B, Ketter R, Idoate Gastearena MA, Lamszus K, Seiz-Rosenhagen M, Mawrin C, Harter PN, Felsberg J, Hänggi D, Herold-Mende C, Berghoff AS, Weller M, Pfister SM, Wick W, Reifenberger G, Preusser M, von Deimling A, Sahm F.

Acta Neuropathol. 2018 Dec;136(6):975-978. doi: 10.1007/s00401-018-1924-x. Epub 2018 Oct 31. No abstract available.

PMID:
30382370
12.

Intertumoral Heterogeneity in SCLC Is Influenced by the Cell Type of Origin.

Yang D, Denny SK, Greenside PG, Chaikovsky AC, Brady JJ, Ouadah Y, Granja JM, Jahchan NS, Lim JS, Kwok S, Kong CS, Berghoff AS, Schmitt A, Reinhardt HC, Park KS, Preusser M, Kundaje A, Greenleaf WJ, Sage J, Winslow MM.

Cancer Discov. 2018 Oct;8(10):1316-1331. doi: 10.1158/2159-8290.CD-17-0987. Epub 2018 Sep 18.

PMID:
30228179
13.

New developments in brain metastases.

Berghoff AS, Preusser M.

Ther Adv Neurol Disord. 2018 Jun 28;11:1756286418785502. doi: 10.1177/1756286418785502. eCollection 2018. Review.

14.

Temporal muscle thickness is an independent prognostic marker in melanoma patients with newly diagnosed brain metastases.

Furtner J, Berghoff AS, Schöpf V, Reumann R, Pascher B, Woitek R, Asenbaum U, Pelster S, Leitner J, Widhalm G, Gatterbauer B, Dieckmann K, Höller C, Prayer D, Preusser M.

J Neurooncol. 2018 Oct;140(1):173-178. doi: 10.1007/s11060-018-2948-8. Epub 2018 Jul 14.

15.

Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate.

Bunse L, Pusch S, Bunse T, Sahm F, Sanghvi K, Friedrich M, Alansary D, Sonner JK, Green E, Deumelandt K, Kilian M, Neftel C, Uhlig S, Kessler T, von Landenberg A, Berghoff AS, Marsh K, Steadman M, Zhu D, Nicolay B, Wiestler B, Breckwoldt MO, Al-Ali R, Karcher-Bausch S, Bozza M, Oezen I, Kramer M, Meyer J, Habel A, Eisel J, Poschet G, Weller M, Preusser M, Nadji-Ohl M, Thon N, Burger MC, Harter PN, Ratliff M, Harbottle R, Benner A, Schrimpf D, Okun J, Herold-Mende C, Turcan S, Kaulfuss S, Hess-Stumpp H, Bieback K, Cahill DP, Plate KH, Hänggi D, Dorsch M, Suvà ML, Niemeyer BA, von Deimling A, Wick W, Platten M.

Nat Med. 2018 Aug;24(8):1192-1203. doi: 10.1038/s41591-018-0095-6. Epub 2018 Jul 9.

PMID:
29988124
16.

Large-scale database mining reveals hidden trends and future directions for cancer immunotherapy.

Kather JN, Berghoff AS, Ferber D, Suarez-Carmona M, Reyes-Aldasoro CC, Valous NA, Rojas-Moraleda R, Jäger D, Halama N.

Oncoimmunology. 2018 Mar 29;7(7):e1444412. doi: 10.1080/2162402X.2018.1444412. eCollection 2018.

17.

The PERSONS score for symptoms assessment in simultaneous care setting: A pilot study.

Cortellini A, Porzio G, Masel EK, Berghoff AS, Knotzer B, Parisi A, Pavese F, Ficorella C, Verna L.

Palliat Support Care. 2019 Feb;17(1):82-86. doi: 10.1017/S1478951518000238. Epub 2018 May 24.

PMID:
29792235
18.

PD-1 and PD-L1 expression in HNSCC primary cancer and related lymph node metastasis - impact on clinical outcome.

Schneider S, Kadletz L, Wiebringhaus R, Kenner L, Selzer E, Füreder T, Rajky O, Berghoff AS, Preusser M, Heiduschka G.

Histopathology. 2018 Oct;73(4):573-584. doi: 10.1111/his.13646. Epub 2018 Jul 4.

PMID:
29742291
19.

Diagnostic value of 18F-fluordesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site.

Wolpert F, Weller M, Berghoff AS, Rushing E, Füreder LM, Petyt G, Leske H, Andratschke N, Regli L, Neidert MC, Stupp R, Stahel R, Dummer R, Frauenfelder T, Roth P, Reyns N, Kaufmann PA, Preusser M, Le Rhun E.

Eur J Cancer. 2018 Jun;96:64-72. doi: 10.1016/j.ejca.2018.03.010. Epub 2018 Apr 17.

PMID:
29677642
20.

Anti-angiogenic therapies in brain metastases.

Berghoff AS, Preusser M.

Memo. 2018;11(1):14-17. doi: 10.1007/s12254-018-0384-2. Epub 2018 Feb 2. Review.

21.

Toward Precision Medicine in Brain Metastases.

Berghoff AS, Brastianos PK.

Semin Neurol. 2018 Feb;38(1):95-103. doi: 10.1055/s-0038-1627469. Epub 2018 Mar 16. Review.

PMID:
29548056
22.

Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey.

Levy A, Faivre-Finn C, Hasan B, De Maio E, Berghoff AS, Girard N, Greillier L, Lantuéjoul S, O'Brien M, Reck M, Dingemans AC, Novello S, Berghmans T, Besse B, Hendriks L; Young Investigators EORTC Lung Cancer Group (YI EORTC LCG).

Eur J Cancer. 2018 Apr;93:37-46. doi: 10.1016/j.ejca.2018.01.067. Epub 2018 Feb 21.

PMID:
29477100
23.

Role of the blood-brain barrier in metastatic disease of the central nervous system.

Berghoff AS, Preusser M.

Handb Clin Neurol. 2018;149:57-66. doi: 10.1016/B978-0-12-811161-1.00004-9. Review.

PMID:
29307361
24.

Educational video: the role of PD-L1 in the local tumour microenvironment.

Preusser M, Berghoff AS, Thallinger C, Zielinski CC.

ESMO Open. 2017 Feb 1;1(6):e000137. doi: 10.1136/esmoopen-2016-000137. eCollection 2016.

25.

CECOG educational illustrations: the blood-brain barrier and its relevance for targeted cancer therapies and immuno-oncology.

Preusser M, Berghoff AS, Thallinger C, Zielinski C.

ESMO Open. 2017 Jun 8;2(2):e000194. doi: 10.1136/esmoopen-2017-000194. eCollection 2017.

26.

Correlation of immune phenotype with IDH mutation in diffuse glioma.

Berghoff AS, Kiesel B, Widhalm G, Wilhelm D, Rajky O, Kurscheid S, Kresl P, Wöhrer A, Marosi C, Hegi ME, Preusser M.

Neuro Oncol. 2017 Oct 19;19(11):1460-1468. doi: 10.1093/neuonc/nox054.

27.

Next-Generation Sequencing-based genomic profiling of brain metastases of primary ovarian cancer identifies high number of BRCA-mutations.

Balendran S, Liebmann-Reindl S, Berghoff AS, Reischer T, Popitsch N, Geier CB, Kenner L, Birner P, Streubel B, Preusser M.

J Neurooncol. 2017 Jul;133(3):469-476. doi: 10.1007/s11060-017-2459-z. Epub 2017 May 11.

28.

Decreased body mass index is associated with impaired survival in lung cancer patients with brain metastases: A retrospective analysis of 624 patients.

Masel EK, Berghoff AS, Füreder LM, Heicappell P, Schlieter F, Widhalm G, Gatterbauer B, Dieckmann U, Birner P, Bartsch R, Schur S, Watzke HH, Zielinski CC, Preusser M.

Eur J Cancer Care (Engl). 2017 Nov;26(6). doi: 10.1111/ecc.12707. Epub 2017 May 10.

PMID:
28488812
29.

Targeted Therapies for Melanoma Brain Metastases.

Berghoff AS, Preusser M.

Curr Treat Options Neurol. 2017 Apr;19(4):13. doi: 10.1007/s11940-017-0449-2. Review.

30.

DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis.

Sahm F, Schrimpf D, Stichel D, Jones DTW, Hielscher T, Schefzyk S, Okonechnikov K, Koelsche C, Reuss DE, Capper D, Sturm D, Wirsching HG, Berghoff AS, Baumgarten P, Kratz A, Huang K, Wefers AK, Hovestadt V, Sill M, Ellis HP, Kurian KM, Okuducu AF, Jungk C, Drueschler K, Schick M, Bewerunge-Hudler M, Mawrin C, Seiz-Rosenhagen M, Ketter R, Simon M, Westphal M, Lamszus K, Becker A, Koch A, Schittenhelm J, Rushing EJ, Collins VP, Brehmer S, Chavez L, Platten M, Hänggi D, Unterberg A, Paulus W, Wick W, Pfister SM, Mittelbronn M, Preusser M, Herold-Mende C, Weller M, von Deimling A.

Lancet Oncol. 2017 May;18(5):682-694. doi: 10.1016/S1470-2045(17)30155-9. Epub 2017 Mar 15.

31.

Validation of nuclear STAT6 immunostaining as a diagnostic marker of meningeal solitary fibrous tumor (SFT)/hemangiopericytoma.

Berghoff AS, Kresl P, Bienkowski M, Koelsche C, Rajky U, Hainfellner JA, Preusser M.

Clin Neuropathol. 2017 Mar/Apr;36 (2017)(2):56-59. doi: 10.5414/NP300993.

PMID:
28128724
32.

Combining standard clinical blood values for improving survival prediction in patients with newly diagnosed brain metastases-development and validation of the LabBM score.

Berghoff AS, Wolpert F, Holland-Letz T, Koller R, Widhalm G, Gatterbauer B, Dieckmann K, Birner P, Bartsch R, Zielinski CC, Weller M, Preusser M.

Neuro Oncol. 2017 Sep 1;19(9):1255-1262. doi: 10.1093/neuonc/now290.

33.

Survival prediction using temporal muscle thickness measurements on cranial magnetic resonance images in patients with newly diagnosed brain metastases.

Furtner J, Berghoff AS, Albtoush OM, Woitek R, Asenbaum U, Prayer D, Widhalm G, Gatterbauer B, Dieckmann K, Birner P, Aretin B, Bartsch R, Zielinski CC, Schöpf V, Preusser M.

Eur Radiol. 2017 Aug;27(8):3167-3173. doi: 10.1007/s00330-016-4707-6. Epub 2017 Jan 3.

34.

Cancer immune cycle: a video introduction to the interaction between cancer and the immune system.

Preusser M, Berghoff AS, Thallinger C, Zielinski CC.

ESMO Open. 2016 Apr 12;1(3):e000056. eCollection 2016.

35.

Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers.

Berghoff AS, Schur S, Füreder LM, Gatterbauer B, Dieckmann K, Widhalm G, Hainfellner J, Zielinski CC, Birner P, Bartsch R, Preusser M.

ESMO Open. 2016 Mar 16;1(2):e000024. eCollection 2016.

36.

Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC).

Berghoff AS, Ricken G, Wilhelm D, Rajky O, Widhalm G, Dieckmann K, Birner P, Bartsch R, Preusser M.

J Neurooncol. 2016 Oct;130(1):19-29. Epub 2016 Jul 19.

PMID:
27436101
37.

In search of a target: PD-1 and PD-L1 profiling across glioma types.

Berghoff AS, Preusser M.

Neuro Oncol. 2016 Oct;18(10):1331-2. doi: 10.1093/neuonc/now162. Epub 2016 Aug 17. No abstract available.

38.

Impact of Blood-Brain Barrier Integrity on Tumor Growth and Therapy Response in Brain Metastases.

Osswald M, Blaes J, Liao Y, Solecki G, Gömmel M, Berghoff AS, Salphati L, Wallin JJ, Phillips HS, Wick W, Winkler F.

Clin Cancer Res. 2016 Dec 15;22(24):6078-6087. Epub 2016 Aug 12.

39.

Tumor-infiltrating lymphocyte subsets and tertiary lymphoid structures in pulmonary metastases from colorectal cancer.

Schweiger T, Berghoff AS, Glogner C, Glueck O, Rajky O, Traxler D, Birner P, Preusser M, Klepetko W, Hoetzenecker K.

Clin Exp Metastasis. 2016 Oct;33(7):727-39. doi: 10.1007/s10585-016-9813-y. Epub 2016 Jul 23.

40.

Immune Checkpoint Inhibitors in Brain Metastases: From Biology to Treatment.

Berghoff AS, Venur VA, Preusser M, Ahluwalia MS.

Am Soc Clin Oncol Educ Book. 2016;35:e116-22. doi: 10.14694/EDBK_100005. Review.

41.

Prognostic impact of breast cancer subtypes in elderly patients.

Bergen ES, Tichy C, Berghoff AS, Rudas M, Dubsky P, Bago-Horvath Z, Mader RM, Exner R, Gnant M, Zielinski CC, Steger GG, Preusser M, Bartsch R.

Breast Cancer Res Treat. 2016 May;157(1):91-9. doi: 10.1007/s10549-016-3787-y. Epub 2016 Apr 23.

42.

A Cross-Sectional Study of Patients' Satisfaction With Totally Implanted Access Ports.

Minichsdorfer C, Füreder T, Mähr B, Berghoff AS, Heynar H, Dressler A, Gnant M, Zielinski C, Bartsch R.

Clin J Oncol Nurs. 2016 Apr;20(2):175-80. doi: 10.1188/16.CJON.175-180.

PMID:
26991711
43.

Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases.

Berghoff AS, Fuchs E, Ricken G, Mlecnik B, Bindea G, Spanberger T, Hackl M, Widhalm G, Dieckmann K, Prayer D, Bilocq A, Heinzl H, Zielinski C, Bartsch R, Birner P, Galon J, Preusser M.

Oncoimmunology. 2015 Jun 9;5(1):e1057388. eCollection 2016.

44.

Genetic variants associated with colorectal brain metastases susceptibility and survival.

Stremitzer S, Berghoff AS, Volz NB, Zhang W, Yang D, Stintzing S, Ning Y, Sunakawa Y, Yamauchi S, Sebio A, Matsusaka S, Okazaki S, Hanna D, Parekh A, Mendez A, Berger MD, El-Khoueiry R, Birner P, Preusser M, Lenz HJ.

Pharmacogenomics J. 2017 Jan;17(1):29-35. doi: 10.1038/tpj.2015.86. Epub 2015 Dec 22.

PMID:
26689941
45.

Impact of oncogenic BRAF mutations and p16 expression on the growth rate of early melanomas and naevi in vivo.

Tschandl P, Berghoff AS, Preusser M, Pammer J, Pehamberger H, Kittler H.

Br J Dermatol. 2016 Feb;174(2):364-70. doi: 10.1111/bjd.14323. Epub 2016 Jan 9.

PMID:
26613644
46.

The PERS(2) ON score for systemic assessment of symptomatology in palliative care: a pilot study.

Masel EK, Berghoff AS, Schur S, Maehr B, Schrank B, Simanek R, Preusser M, Marosi C, Watzke HH.

Eur J Cancer Care (Engl). 2016 Jul;25(4):544-50. doi: 10.1111/ecc.12419. Epub 2015 Nov 12.

PMID:
26564404
47.

Brain tumour cells interconnect to a functional and resistant network.

Osswald M, Jung E, Sahm F, Solecki G, Venkataramani V, Blaes J, Weil S, Horstmann H, Wiestler B, Syed M, Huang L, Ratliff M, Karimian Jazi K, Kurz FT, Schmenger T, Lemke D, Gömmel M, Pauli M, Liao Y, Häring P, Pusch S, Herl V, Steinhäuser C, Krunic D, Jarahian M, Miletic H, Berghoff AS, Griesbeck O, Kalamakis G, Garaschuk O, Preusser M, Weiss S, Liu H, Heiland S, Platten M, Huber PE, Kuner T, von Deimling A, Wick W, Winkler F.

Nature. 2015 Dec 3;528(7580):93-8. doi: 10.1038/nature16071. Epub 2015 Nov 4.

PMID:
26536111
48.

Clinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma?

Preusser M, Berghoff AS, Wick W, Weller M.

Clin Neuropathol. 2015 Nov-Dec;34(6):313-21. Review.

49.

Psyche at the end of life: Psychiatric symptoms are prevalent in patients admitted to a palliative care unit.

Masel EK, Berghoff AS, Mladen A, Schur S, Maehr B, Kirchhoff M, Simanek R, Bauer M, Watzke HH, Amering M.

Palliat Support Care. 2016 Jun;14(3):250-8. doi: 10.1017/S1478951515000899. Epub 2015 Oct 8.

PMID:
26447347
50.

Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma.

Furtner J, Schöpf V, Seystahl K, Le Rhun E, Rudà R, Roelcke U, Koeppen S, Berghoff AS, Marosi C, Clement P, Faedi M, Watts C, Wick W, Soffietti R, Weller M, Preusser M.

Neuro Oncol. 2016 Mar;18(3):401-7. doi: 10.1093/neuonc/nov183. Epub 2015 Sep 9.

Supplemental Content

Loading ...
Support Center